Illumina Inc. has entered into an agreement with a Beijing diagnostics firm that will employ next-generation sequencing technology to improve health care in China.
Illumina will be working with Annoroad to develop a user-friendly prenatal DNA diagnostic system for the Chinese market.
Illumina said next-generation sequencing (NGS) technology has evolved rapidly in recent years and is now regarded as an essential factor for enabling precision medicine.
As part of the agreement, Annoroad will provide its nucleic acid extraction, library preparation and data analysis software while Illumina will provide NGS instrument components and related reagents.
Annoroad has developed an array of NGS diagnostic applications in the field of human reproduction, cancer and rare diseases.
Illumina’s (Nasdaq: ILMN) goal is to improve human health by working with the genome. It serves customers in the research, clinical and applied markets.